Maze Therapeutics (MAZE) Other Non Operating Income (2024 - 2026)
Maze Therapeutics (MAZE) posted Other Non Operating Income of $2.3 million for Q1 2026, up 2658.82% sequentially from $85000.0 in Q4 2025, and down 10.33% YoY from $2.6 million in Q1 2025.
Maze Therapeutics (MAZE) Other Non Operating Income (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Other Non Operating Income for 3 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Other Non Operating Income fell 10.33% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 266.32% YoY) and the FY2025 annual result came in at $85000.0, up 100.96% from the prior year.
- Other Non Operating Income improved to $2.3 million in Q1 2026 per MAZE's latest filing, from $85000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $2.6 million in Q1 2025 and troughed at -$4.8 million in Q1 2024.
- A 3-year average of -$541714.3 and a median of $85000.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2025 and 2026: Other Non Operating Income soared 154.93% in 2025, then decreased 10.33% in 2026.
- Over 3 years, Other Non Operating Income stood at -$1.6 million in 2024, then jumped by 105.17% to $85000.0 in 2025, then soared by 2658.82% to $2.3 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $2.3 million, $85000.0, and $2.6 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.31 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Dec 31, 2025 | 85,000.00 |
| Mar 31, 2025 | 2.62 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Sep 30, 2024 | -2.65 Mn |
| Jun 30, 2024 | 216,000.00 |
| Mar 31, 2024 | -4.76 Mn |